AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18028044 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS)
Number of subjects: 506
Study 18028044 — intervention group
Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia (IV PCA)
Number of subjects: 506
Study 15704203 — intervention group
Group type: EXPERIMENTAL
Intervention: Denufosol (10, 20, 40, and 60 mg, administered by inhalation via the Pari LC Star nebulizer)
Number of subjects: 61
Study 15704203 — intervention group
Group type: EXPERIMENTAL
Intervention: Denufosol (maximum tolerated dose)
Number of subjects: 61
Study 15704203 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 61
Study 15704203 — intervention group
Group type: COMPARATOR
Intervention: Denufosol and Placebo
Number of subjects: 61
Study 12013151 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 800 mg/day plus naproxen 500 mg/day
Number of subjects: 24
Study 12013151 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg/day
Number of subjects: 24
Study 9925227 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based histology atlas
Number of subjects: 0
Study 9925227 — intervention group
Group type: COMPARATOR
Intervention: No computer-based histology atlas (control group)
Number of subjects: 0
Study 7588504 — intervention group
Group type: EXPERIMENTAL
Intervention: High-amylose corn starch (RS2)
Number of subjects: 24
Study 7588504 — intervention group
Group type: EXPERIMENTAL
Intervention: Extruded and retrograded high-amylose corn starch (RS3)
Number of subjects: 24
Study 7588504 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 24
Study 7588504 — intervention group
Group type: EXPERIMENTAL
Intervention: RS2
Number of subjects: 24
Study 1702916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pygeum africanum extract (50 mg capsules, 1 capsule in the morning and 1 capsule in the evening for 60 days)
Number of subjects: 263
Study 1702916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 capsule in the morning and 1 capsule in the evening for 60 days)
Number of subjects: 263
Study 531221 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 microgram (155)-methyl PGF2 alpha methyl ester (U-36,384) via slow release vaginal suppository
Number of subjects: 20
Study 531221 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microgram 16-phenoxy-omega-tetranor PGE2 methyl sulfonylamide (Sulproston) via intramuscular injection at 4 hour intervals, totaling 1250 +/- 154 microgram
Number of subjects: 20
Study 31478764 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone fixed group (with PSIS fixed DRF)
Number of subjects: 100
Study 31478764 — intervention group
Group type: COMPARATOR
Intervention: Skin fixed group (with cutaneously fixed DRF)
Number of subjects: 100
Study 31478764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 31478764 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin fixed DRF
Number of subjects: 100
Study 29405667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 55
Study 29405667 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 50 µg/kg
Number of subjects: 55
Study 29405667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 55
Study 29405667 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 55
Study 26844419 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS of the motor cortex
Number of subjects: 30
Study 26844419 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) tDCS
Number of subjects: 30
Study 24718736 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexion at 90° for the first 6 hours after surgery
Number of subjects: 100
Study 24718736 — intervention group
Group type: COMPARATOR
Intervention: Knee extension for the first 6 hours after surgery (Control)
Number of subjects: 100
Study 22244638 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐Adjusting File (SAF)
Number of subjects: 20
Study 22244638 — intervention group
Group type: COMPARATOR
Intervention: ProTaper file system
Number of subjects: 20
Study 19878447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 1067
Study 19878447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 1067
Study 19878447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1067
Study 17709859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pedicle screw fixation feasibility
Number of subjects: 80
Study 15814549 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus and MMF
Number of subjects: 205
Study 15814549 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporin ME and MMF
Number of subjects: 205
Study 15814549 — intervention group
Group type: COMPARATOR
Intervention: corticosteroid therapy
Number of subjects: 205
Study 12488788 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer patients
Number of subjects: 20
Study 12488788 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 20
Study 9813557 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (30 micrograms/min)
Number of subjects: 9
Study 9813557 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (90 micrograms/min)
Number of subjects: 9
Study 9813557 — intervention group
Group type: COMPARATOR
Intervention: Lower body negative pressure
Number of subjects: 9
Study 7709947 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated catheter (5% silver oxide)
Number of subjects: 1309
Study 7709947 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard silicone elastomer-coated latex catheter)
Number of subjects: 1309
Study 7709947 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated catheter (5% silver oxide) in women not receiving antibiotics
Number of subjects: 1309
Study 7709947 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard silicone elastomer-coated latex catheter) in women not receiving antibiotics
Number of subjects: 1309
Study 7709947 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-coated catheter (5% silver oxide) in men not receiving antibiotics
Number of subjects: 1309
Study 7709947 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard silicone elastomer-coated latex catheter) in men not receiving antibiotics
Number of subjects: 1309
Study 2704247 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (0.009 mg/kg)
Number of subjects: 0
Study 2704247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 342185 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 50
Study 342185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30338354 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support via telephone (1 to 5 times according to preference)
Number of subjects: 260
Study 30338354 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 260
Study 29527812 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-incision negative pressure therapy (ciNPT)
Number of subjects: 132
Study 29527812 — intervention group
Group type: COMPARATOR
Intervention: Control group with conventional dressing
Number of subjects: 132
Study 26945586 — intervention group
Group type: COMPARATOR
Intervention: COMPASS program (multi-component curriculum-based safe spaces program)
Number of subjects: 1805
Study 26945586 — intervention group
Group type: COMPARATOR
Intervention: COMPASS program (including caregiver component)
Number of subjects: 1805
Study 26945586 — intervention group
Group type: COMPARATOR
Intervention: COMPASS program
Number of subjects: 1805
Study 24934734 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous aspiration thrombectomy (PAT) followed by standard anticoagulant therapy
Number of subjects: 42
Study 24934734 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation therapy alone
Number of subjects: 42
Study 22317489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 120
Study 22317489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 21413416 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (7.5‐15 mg)
Number of subjects: 60
Study 21413416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21413416 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 mg)
Number of subjects: 60
Study 17328989 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg daily as maintenance therapy
Number of subjects: 30
Study 16534857 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 34
Study 16534857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12612903 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (3 MU 3 times a week) plus 1000‐1200 mg/day ribavirin for 1 year
Number of subjects: 52
Study 12612903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 52
Study 12612903 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b plus ribavirin
Number of subjects: 52
Study 10234597 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily by mouth
Number of subjects: 12
Study 10234597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10159739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation in the ambulance
Number of subjects: 20
Study 10159739 — intervention group
Group type: COMPARATOR
Intervention: Intubation in the rescue squad station
Number of subjects: 20
Study 1677267 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bunazosin 0.3%
Number of subjects: 15
Study 1677267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6658949 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant (AC)
Number of subjects: 241
Study 6658949 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 241
Study 6658949 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AC and ASA
Number of subjects: 241
Study 31775685 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-based self-help Problem Solving Therapy (PST) for 5 weeks
Number of subjects: 206
Study 31775685 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 206
Study 31775685 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-based self-help Problem Solving Therapy (PST)
Number of subjects: 206
Study 28427734 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602
Study 28427734 — intervention group
Group type: COMPARATOR
Intervention: Heparin and glycoprotein IIb/IIIa inhibitor
Number of subjects: 3602
Study 28427734 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 3602
Study 26168496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 30 mg/m² and irinotecan (CPT‐11) 50 mg/m²
Number of subjects: 6
Study 23425430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC)
Number of subjects: 690
Study 23425430 — intervention group
Group type: COMPARATOR
Intervention: Brinzolamide 1%
Number of subjects: 690
Study 23425430 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine 0.2%
Number of subjects: 690
Study 23425430 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 690
Study 21271174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.1 µg/kg)
Number of subjects: 60
Study 21271174 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.5 µg/kg)
Number of subjects: 60
Study 19553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatments
Number of subjects: 0
Study 19553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study 19553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based care (psychological and psychopharmacological approaches)
Number of subjects: 0
Study 19553878 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible combination of antidepressants and psychotherapy
Number of subjects: 0
Study 19553878 — intervention group
Group type: EXPERIMENTAL
Intervention: No single treatment identified
Number of subjects: 0
Study 17526548 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support system (CDSS) for managing renal anaemia, including treatment algorithms for Epoetin doses and iron supplements.
Number of subjects: 0
Study 17526548 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical measures of haemodialysis (HD) and peritoneal dialysis (PD).
Number of subjects: 0
Study 15213038 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss group with high calcium intake (HiCa: 1.8 g/d)
Number of subjects: 73
Study 15213038 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss group with normal calcium intake (NlCa: 1 g/d)
Number of subjects: 73
Study 15213038 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance group (WM)
Number of subjects: 73
Study 12362493 — intervention group
Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 0
Study 12362493 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine episiotomy
Number of subjects: 0
Study 9671875 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus antiandrogen therapy
Number of subjects: 813
Study 9671875 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide plus antiandrogen therapy
Number of subjects: 813
Study 9671875 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide plus flutamide therapy
Number of subjects: 813
Study 9671875 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus bicalutamide therapy
Number of subjects: 813
Study 9671875 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin plus flutamide therapy
Number of subjects: 813
Study 9671875 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide plus bicalutamide therapy
Number of subjects: 813
Study 8044010 — intervention group
Group type: EXPERIMENTAL
Intervention: Xijian Tongshuan pill (XJTS)
Number of subjects: 70
Study 8044010 — intervention group
Group type: COMPARATOR
Intervention: Dextranum and Venoruton (Control group A)
Number of subjects: 70
Study 8044010 — intervention group
Group type: COMPARATOR
Intervention: Cyclandelate capsule (Control group B)
Number of subjects: 70
Study 2585558 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal tracheal Combitube (ETC)
Number of subjects: 12
Study 2585558 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal airway (ETA)
Number of subjects: 12
Study 2585558 — intervention group
Group type: COMPARATOR
Intervention: Mask ventilation
Number of subjects: 12
Study 1095514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine (210 mg daily for 20 days)
Number of subjects: 49
Study 1095514 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (150 mg daily for 20 days)
Number of subjects: 49
Study 30744268 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk intake at breakfast
Number of subjects: 22315
Study 30744268 — intervention group
Group type: COMPARATOR
Intervention: No milk intake at breakfast
Number of subjects: 22315
Study 28264794 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional video consent
Number of subjects: 665
Study 28264794 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff video consent
Number of subjects: 665
Study 28264794 — intervention group
Group type: COMPARATOR
Intervention: Standard consent
Number of subjects: 665
Study 28264794 — intervention group
Group type: COMPARATOR
Intervention: FAQ consent
Number of subjects: 665
Study 25720929 — intervention group
Group type: EXPERIMENTAL
Intervention: FUSION BIOLINE heparin-coated vascular graft
Number of subjects: 209
Study 25720929 — intervention group
Group type: COMPARATOR
Intervention: Standard expanded polytetrafluoroethylene (ePTFE) graft
Number of subjects: 209
Study 24261913 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 140
Study 24261913 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 140
Study 21826017 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported Chronic Heart Questionnaire (CHQ-SR)
Number of subjects: 54
Study 21826017 — intervention group
Group type: COMPARATOR
Intervention: Exercise rehabilitation
Number of subjects: 54
Study 18853147 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 50
Study 18853147 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 50
Study 17304149 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg daily for 6 days
Number of subjects: 13
Study 17304149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15085466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 anti‐Xa U/kg subcutaneously for 7 days
Number of subjects: 0
Study 15085466 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 anti‐Xa U/kg subcutaneously for 90 days
Number of subjects: 0
Study 15085466 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous unfractionated heparin (UFH) for 5 days
Number of subjects: 0
Study 15085466 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin for 3 months
Number of subjects: 0
Study 11499187 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral feedback
Number of subjects: 0
Study 11499187 — intervention group
Group type: EXPERIMENTAL
Intervention: Written feedback
Number of subjects: 0
Study 11499187 — intervention group
Group type: EXPERIMENTAL
Intervention: Any feedback (oral or written)
Number of subjects: 0
Study 11499187 — intervention group
Group type: EXPERIMENTAL
Intervention: Written feedback with awards
Number of subjects: 0
Study 11499187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 0
Study 9773835 — intervention group
Group type: EXPERIMENTAL
Intervention: Food allergy diagnosis based on clinical response to double-blind placebo-controlled food challenge.
Number of subjects: 31
Study 9773835 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal IgE-positive cells measurement.
Number of subjects: 31
Study 9773835 — intervention group
Group type: EXPERIMENTAL
Intervention: Total serum IgE levels measurement.
Number of subjects: 31
Study 9773835 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of total serum IgE levels with IgE-positive cells.
Number of subjects: 31
Study 9773835 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed reactions to food.
Number of subjects: 31
Study 9773835 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic reactions to foods.
Number of subjects: 31
Study 9773835 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive value of IgE-positive cells in allergy diagnosis.
Number of subjects: 31
Study 7840913 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir 600 mg in combination with zidovudine
Number of subjects: 202
Study 7840913 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir 200 mg in combination with zidovudine
Number of subjects: 202
Study 7840913 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir 600 mg alone
Number of subjects: 202
Study 7840913 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (various doses: 25, 75, 200, 600 mg)
Number of subjects: 202
Study 7840913 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 202
Study 2150891 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol-ipratropium nebulization
Number of subjects: 120
Study 2150891 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 120
Study 177866 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenine arabinoside
Number of subjects: 2
Study 31505120 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 43
Study 31505120 — intervention group
Group type: COMPARATOR
Intervention: MICT
Number of subjects: 43
Study 30846659 — intervention group
Group type: EXPERIMENTAL
Intervention: ChromaGen blue filter lens
Number of subjects: 40
Study 30846659 — intervention group
Group type: COMPARATOR
Intervention: No ChromaGen blue filter lens
Number of subjects: 40
Study 29465203 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective lung ventilation (PLV)
Number of subjects: 66
Study 29465203 — intervention group
Group type: COMPARATOR
Intervention: Conventional lung ventilation (CLV)
Number of subjects: 66
Study 29465203 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive bronchoscopy (PB)
Number of subjects: 66
Study 25922420 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg oral MDMA
Number of subjects: 35
Study 25922420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 23724547 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Silorane
Number of subjects: 50
Study 23724547 — intervention group
Group type: COMPARATOR
Intervention: Ceram.X Duo
Number of subjects: 50
Study 22813412 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 72
Study 19335074 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/ml rhPDGF‐BB + beta‐TCP + bioabsorbable collagen wound‐healing dressing
Number of subjects: 30
Study 19335074 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (CTG) + coronally advanced flap (CAF)
Number of subjects: 30
Study 17578566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 17578566 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP (2 g per dosage)
Number of subjects: 33
Study 17578566 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (1 g per dosage)
Number of subjects: 33
Study 17578566 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no indomethacin, no ATP/adenosine)
Number of subjects: 33
Study 14760130 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.3 microg/kg
Number of subjects: 161
Study 14760130 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 1 microg/kg
Number of subjects: 161
Study 14760130 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 3 microg/kg
Number of subjects: 161